Hen­grui and Kail­era’s in­ject­ed in­cretin posts best-in-class obe­si­ty da­ta in Phase 2 tri­al

At 22.8% at 36 weeks, the weight loss seen with Chi­nese drug­mak­er Jiang­su Hen­grui Phar­ma­ceu­ti­cals’ in­ject­ed GLP-1/GIP dual ag­o­nist in its Phase 2 tri­al looks …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER